Halozyme Therapeutics, Inc. — Q2 2011 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2011. The company develops recombinant human enzymes, including rHuPH20, for proprietary therapies and partnered drug-delivery programs. Financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Total revenue | $23.19 million | $3.21 million | $30.73 million | $6.66 million |
| Operating income (loss) | $3.10 million | $(12.15) million | $(6.56) million | $(23.94) million |
| Net income (loss) | $3.12 million | $(12.15) million | $(6.52) million | $(23.94) million |
| Net income (loss) per share | $0.03 | $(0.13) | $(0.06) | $(0.26) |
- Revenue growth was principally collaboration-related, not product-led: Q2 included $18.0 million of upfront fees from the new ViroPharma and Intrexon agreements. Six-month revenue also included $8.0 million of Roche and Baxter milestone payments.
- Product sales were only $165,000 in Q2 and $331,000 for the first half, down 18% and 45%, respectively. The HYLENEX partnership termination left ICSI Cumulase as the primary product-sales source until HYLENEX is reintroduced.
- Research and development expense was $15.35 million in Q2 and $29.13 million for the first half, increases of 29% and 24%. Management attributed much of the increase to clinical-trial and manufacturing activity, especially the ultrafast insulin program. SG&A was $4.57 million and $7.97 million, up 35% and 12%.
- Q2 operating and net profitability reflected collaboration revenue; the company continued to report a six-month loss and had an accumulated deficit of $231.8 million. Product sales alone remained small relative to operating expenses.
- Cash and cash equivalents were $79.12 million at June 30, versus $83.26 million at December 31, 2010. Six-month operating cash use was $7.35 million, compared with $26.39 million in the prior-year period; investing cash use was $0.23 million and financing cash provided by option exercises was $3.45 million.
- Current assets were $88.01 million and current liabilities $31.54 million. The balance sheet reported no debt line item. Total deferred revenue was $57.63 million, including $20.35 million classified as current.
Material changes and unusual items
- In January 2011, Halozyme and Baxter terminated the HYLENEX partnership. Following a July 18 transition agreement, Baxter relinquished return rights and Halozyme had no further HYLENEX partnership performance obligations. The company expected to recognize about $7.6 million of deferred upfront fees and $9.3 million of deferred product-based payments as collaboration revenue, plus about $991,000 as product revenue, in Q3 2011.
- The FDA approved the submitted data supporting HYLENEX reintroduction. Management expected reintroduction by year-end 2011; Baxter was to fill and finish the product under a supply agreement while Halozyme pursued manufacturing technology transfer.
- From January 1, 2011, new or materially modified collaboration agreements were accounted for under the relative-selling-price method, and substantive milestone payments could be recognized when achieved. The company said this produced materially different revenue-recognition patterns for ViroPharma and Intrexon than for older arrangements. The $18 million upfront fees were recognized in Q2.
- Cash-based revenue timing remains uncertain because partner-requested research services and API supply, milestone achievement, and partner development determine when revenue is earned. Most collaboration partners may terminate on 90 days’ notice.
Outlook, management commentary and risks
- Management forecast 2011 net cash burn of approximately $30 million to $35 million and said existing cash should fund operations for at least 12 months. It also stated revenues were not expected to fund operations for several years. Up to $39.8 million remained available under the company’s shelf registration statement.
- Management expected R&D expense to increase slightly as clinical programs advanced and SG&A to rise with planned sales and marketing activity. It cautioned that development costs, timing, regulatory outcomes and future collaboration revenue are uncertain.
- Ultrafast insulin Phase 2 studies were expected to complete by the end of Q3 2011; the company reported encouraging preliminary pump-study findings. A PEGPH20 pancreatic cancer Phase 1b/2 trial was planned for initiation by year-end 2011. Roche expected to report subcutaneous Herceptin Phase 3 results by year-end and had indicated a potential 2012 filing; Baxter filed for U.S. approval of HyQ in Q2.
- Key risks include clinical or regulatory failure or delay, dependence on partners and contract manufacturers, adequate supply and scale-up of rHuPH20, HYLENEX manufacturing and relaunch execution, partner termination, limited product revenues, and the possibility that further capital may be required on unfavorable or dilutive terms.
- Operating leases represented $10.68 million of future minimum payments as of June 30. The company disclosed no material litigation and reported disclosure controls were effective.
Important facts for investors to verify
- Whether HYLENEX was reintroduced by year-end 2011, and whether the transition, supply and manufacturing arrangements supported reliable commercial supply.
- Whether the expected Q3 recognition of approximately $17.9 million in collaboration revenue and $991,000 in product revenue occurred as described.
- Progress and results for the ultrafast insulin, PEGPH20, Roche and Baxter programs against the stated timelines.
- Actual cash burn versus the $30 million to $35 million 2011 estimate, and whether additional financing or use of the shelf became necessary.
- How much future collaboration revenue depends on milestone achievement, partner requests, and agreements that partners may terminate on 90 days’ notice.